Description
By the end of 2017, there were about 330 million hypertensive patients in China, in another word, one in every three adults in China had hypertension. The incidence of hypertension in China rose from 5.1% in 1959 to 37.2% in 2017.
Angiotensin II receptor antagonists (angiotensin receptor blockers, ARBs) are antihypertensive drugs that has been growing rapidly since it emerged in the 1990s. As an important ARB administered orally once a day to treat essential hypertension,
Telmisartan was discovered by Boehringer Ingelheim and first launched in the U.S. as Micardis in 1999. In the same year, in Germany, it was launched by Boehringer Ingelheim and Glaxo Wellcome in the trades name of Micardis and Pritor respectively. Then it was marketed in several countries. The patent for Telmisartan expired in 2014.
At the end of 2000, Boehringer Ingelheim introduced the active pharmaceutical ingredient and preparations of Telmisartan to China. Telmisartan had developed fast since it entered in China. The sales value kept increasing before 2014 when it began to decrease, reaching about CNY 165 million in 2017. At present, China's Telmisartan market is dominated by Boehringer Ingelheim, China Resources Double-Crane Pharmaceutical Co., Ltd., Yichang HEC Changjiang Pharmaceutical Co., Ltd., and Jiangsu Wanbang Biopharmaceuticals Co., Ltd. Boehringer Ingelheim has the largest market share. In 2017, its market share by sales value was about 72.4% but showed a downward trend. It is expected that with the increasing number of hypertensive patients, China's Telmisartan market will still have some growth potential.
Topics Covered:
- Sales of Telmisartan in China
- Sales of Telmisartan in China by region
- Competitive landscape of China's Telmisartan market
- Prices of Telmisartan in China
- Major factors affecting China's Telmisartan market
- Prospect of China's Telmisartan market
Investigation Report on China's Telmisartan Market, 2018-2022
Table of Contents
1 Relevant Concepts of Telmisartan
1.1 Indications for Telmisartan
1.2 Development of Telmisartan in China
1.3 Governmental Approval of Telmisartan in China
2 Sales of Telmisartan in China, 2013-2017
2.1 Sales Value of Telmisartan
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Telmisartan
2. 2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Telmisartan by Dosage Form in China, 2013-2017
2.3.1 Tablets
2.3.2 Capsules
3 Analysis on Major Telmisartan Manufacturers in China, 2013-2017
3.1 Analysis on Market Share of Major Telmisartan Manufacturers
3.1.1 Market Share by Sales Value
3.1.2 Market Share by Sales Volume
3.2 Boehringer Ingelheim
3.2.1 Enterprise Profile
3.2.2 Sales of Boehringer Ingelheim's Telmisartan in China
3.3 China Resources Double-Crane Pharmaceutical Co., Ltd.
3.3.1 Enterprise Profile
3.3.2 Sales of China Resources Double-Crane Pharmaceutical Co., Ltd.'s Telmisartan in China
3.4 Yichang HEC Changjiang Pharmaceutical Co., Ltd.
3.4.1 Enterprise Profile
3.4.2 Sales of Yichang HEC Changjiang Pharmaceutical Co., Ltd.'s Telmisartan in China
3.5 Jiangsu Wanbang Biopharmaceuticals Co., Ltd.
3.5.1 Enterprise Profile
3.5.2 Sales of Jiangsu Wanbang Biopharmaceuticals Co., Ltd.'s Telmisartan in China
3.6 Suzhou Dawnrays Pharmaceutical Co., Ltd.
3.6.1 Enterprise Profile
3.6.2 Sales of Suzhou Dawnrays Pharmaceutical Co., Ltd.'s Telmisartan in China
4 Prices of Telmisartan in China, 2017-2018
4.1 Boehringer Ingelheim (Micardis)
4.2 China Resources Double-Crane Pharmaceutical Co., Ltd. (Suhe)
4.3 Yichang HEC Changjiang Pharmaceutical Co., Ltd. (Oumeining)
4.4 Jiangsu Wanbang Biopharmaceuticals Co., Ltd. (Bangtan)
4.5 Suzhou Dawnrays Pharmaceutical Co., Ltd. (Anneiqiang)
5 Prospect of China's Telmisartan Market, 2018-2022
5.1 Forecast on Market Size
5.2 Forecast on Market Trend
List of Charts
Chart Governmental Approval of Telmisartan in China
Chart Sales of Telmisartan in China, 2013-2017
Chart Sales Value of Telmisartan in Parts of China, 2013-2017
Chart Sales Volume of Telmisartan in China, 2013-2017
Chart Sales Volume of Telmisartan in Parts of China, 2013-2017
Chart Sales Value of Telmisartan Tablets in China, 2013-2017
Chart Sales Volume of Telmisartan Tablets in China, 2013-2017
Chart Sales Value of Telmisartan Capsules in China, 2013-2017
Chart Market Share of Top 5 Telmisartan Manufacturers by Sales Value in China, 2013-2017
Chart Market Share of Top 5 Telmisartan Manufacturers by Sales Volume in China, 2013-2017
Chart Sales Value of Boehringer Ingelheim's Telmisartan in China, 2013-2017
Chart Sales Volume of Boehringer Ingelheim's Telmisartan in China, 2013-2017
Chart Sales Value of China Resources Double-Crane Pharmaceutical Co., Ltd.'s Telmisartan, 2013-2017
Chart Sales Volume of China Resources Double-Crane Pharmaceutical Co., Ltd.'s Telmisartan, 2013-2017
Chart Sales Value of Yichang HEC Changjiang Pharmaceutical Co., Ltd. 's Telmisartan, 2013-2017
Chart Sales Value of Jiangsu Wanbang Biopharmaceuticals Co., Ltd.'s Telmisartan, 2013-2017
Chart Prices of Boehringer Ingelheim's Telmisartan in Parts of China, 2017-2018
Chart Prices of China Resources Double-Crane Pharmaceutical Co., Ltd.'s Telmisartan in Parts of China, 2017-2018
Chart Prices of Yichang HEC Changjiang Pharmaceutical Co., Ltd.'s Telmisartan in Parts of China, 2017-2018
Chart Forecast on Sales Value of Telmisartan in China, 2018-2022
Global Pulmonary Arterial Hypertension (Pah) Medicine Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 04-Jan-2024 Price: US 3380 Onwards Pages: 103
Market Overview of Global Pulmonary Arterial Hypertension (Pah) Medicine market:
According to our latest research, the global Pulmonary Arterial Hypertension (Pah) Medicine market looks promising in the next 5 years. As of 2022, the global Pulmonary Arterial Hypertension (Pah) Medicine market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years.
This report covers a research time span from 2018 to ......
Global Nifedipine Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 04-Jan-2024 Price: US 3380 Onwards Pages: 102
Market Overview of Global Nifedipine market:
According to our latest research, the global Nifedipine market looks promising in the next 5 years. As of 2022, the global Nifedipine market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years.
This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Nifedipine market, with a systematical de......
Global Amlodipine Besylate Market Research Report 2024
Published: 04-Jan-2024 Price: US 2900 Onwards Pages: 115
The Amlodipine Besylate market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Amlodipine Besylate market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profil......
Pulmonary Arterial Hypertension (PAH) Drugs - Global Market Insights and Sales Trends 2024
Published: 25-Dec-2023 Price: US 3350 Onwards Pages: 112
The global Pulmonary Arterial Hypertension (PAH) Drugs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Pulmonary Arterial Hypertension (PAH) Drugs in various end use industries. The expanding demands from the Hospitals, Clinics and Other,, are propelling Pulmonary Arterial Hypertension (PAH) Drugs market. Inhalation, one of the segments analysed in this report, is projected to record % ......
Captopril API - Global Market Insights and Sales Trends 2024
Published: 25-Dec-2023 Price: US 3350 Onwards Pages: 100
The global Captopril API market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Captopril API in various end use industries. The expanding demands from the Captopril Tablet, Compound Captopril Tablet and Captopril Injection,, are propelling Captopril API market. 98% Captopril API, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the......
Telmisartan - Global Market Insights and Sales Trends 2024
Published: 21-Dec-2023 Price: US 3350 Onwards Pages: 107
The global Telmisartan market size is expected to reach US$ 3631.3 million by 2029, growing at a CAGR of 3.4% from 2023 to 2029. The market is mainly driven by the significant applications of Telmisartan in various end use industries. The expanding demands from the Hospital, Clinic and Others,, are propelling Telmisartan market. Injection, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Freeze-Dried......
Global Ambrisentan Professional Survey Report 2023, Forecast to 2028
Published: 20-Dec-2023 Price: US 3280 Onwards Pages: 106
Ambrisentan is a drug indicated for use in the treatment of pulmonary hypertension. The peptide endothelin constricts muscles in blood vessels, increasing blood pressure. Ambrisentan, which relaxes those muscles, is an endothelin receptor antagonist, and is selective for the type A endothelin receptor.
Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million US......
Global Ambrisentan Market Research Report 2023, Forecast to 2028
Published: 20-Dec-2023 Price: US 2680 Onwards Pages: 132
Ambrisentan is a drug indicated for use in the treatment of pulmonary hypertension. The peptide endothelin constricts muscles in blood vessels, increasing blood pressure. Ambrisentan, which relaxes those muscles, is an endothelin receptor antagonist, and is selective for the type A endothelin receptor.
Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million US......
Global Amlodipine Besylate Professional Survey Report 2023, Forecast to 2028
Published: 20-Dec-2023 Price: US 3280 Onwards Pages: 133
Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technological advancements, new product launches, and market capital flows are compared across scenarios to demonstrate their impact over the forecast period.
D......
SERVICES
Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
Payment Flexibility
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details -
[email protected] / +1 888 391 5441 )
- Ad Hoc
-
- Pay - as - you - go / Bucket Subscriptions
- Fixed Cost for #of reports
- Customize / Personalize as per your needs
